Atorvastatin fails to slow atherosclerosis in pediatric SLE

10/27/2011 | PhysiciansBriefing.com

A study of 221 patients aged 10 to 21 years old with pediatric systemic lupus erythematosus found that taking atorvastatin for three years had no significant effect on subclinical atherosclerosis progression. Researchers failed to find any significant differences in progression of mean-mean common carotid intima-media thickening between those who took atorvastatin and those on placebo, but found reduced high-sensitivity C-reactive protein, low-density lipoprotein and total cholesterol levels in the statin group. The findings appear in the journal Arthritis & Rheumatism.

View Full Article in:

PhysiciansBriefing.com

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Sr Statistician I (US/TB/00/0028/SL)
Abbott
Santa Clara, CA
Food & Drug Associate
Confidential
Washington, D.C., DC
Senior Manager, Gaps in Care
UAW Retiree Medical Benefits Trust
Detroit, MI
Compliance Director
Abbott Laboratories
Santa Clara, CA
Product Development Manager, Disposable Medical Products
ASAHI INTECC, Orange County CA R&D Center
Santa Ana, CA